These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4365556)

  • 1. Morphological and biochemical studies on liver biopsies of parkinsonian patients treated with levodopa and decarboxylase inhibitor.
    Nevalainen T; Riekkinen P; Rinne UK; Sonninen V
    Acta Neurol Scand; 1974; 50(1):122-30. PubMed ID: 4365556
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
    Dupont E; Hansen E; Melsens S; Parkenberg H; Holm P
    Acta Neurol Scand Suppl; 1972; 51():115-7. PubMed ID: 4514334
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
    Holmsen R; Kvan L; Presthus J; Thoresen GB
    Acta Neurol Scand Suppl; 1972; 51():121-2. PubMed ID: 4514336
    [No Abstract]   [Full Text] [Related]  

  • 5. Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
    Gauthier G; Juge O; Birchler A
    Eur Neurol; 1974; 11(3):133-57. PubMed ID: 4839098
    [No Abstract]   [Full Text] [Related]  

  • 6. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current treatment of Parkinson syndrome with L-dopa].
    Gerstendbrand F; Gründig E; Musiol A
    Pol Tyg Lek; 1972 May; 27(21):798-800. PubMed ID: 4555002
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa and pressor amine sensitivity in parkinsonism.
    Reid JL; Calne DB; George CF; Vakil SD
    Clin Pharmacol Ther; 1972; 13(3):400-6. PubMed ID: 5026378
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients.
    Cavagnini F; Peracchi M; Scotti G; Raggi U; Pontiroli AE; Bana R
    J Endocrinol; 1972 Sep; 54(3):425-33. PubMed ID: 5071365
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A; Gillo-Joffroy L; Mars H; Arsenault A
    Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract]   [Full Text] [Related]  

  • 11. [Enzyme demonstration in semi-thin sections].
    Kaufmann P; Stark J
    Acta Histochem; 1972; 42(1):178-81. PubMed ID: 4340768
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 14. Dopa-decarboxylase inhibitors.
    Lancet; 1973 May; 1(7810):979-80. PubMed ID: 4121597
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J; van Praag HM; Schut D; Nienhuis RJ; Lakke JP
    Eur Neurol; 1974; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Parkinsonism with L-dopa and decarboxylase inhibitors. An electrophysiological study.
    Dietrichson P
    Acta Neurol Scand Suppl; 1972; 51():111-3. PubMed ID: 4514333
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
    Marsden CD; Barry PE; Parkes JD; Zilkha KJ
    J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):10-4. PubMed ID: 4691682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How does L-dopa work in parkinsonism?
    Sandler M
    Lancet; 1971 Apr; 1(7703):784. PubMed ID: 4101278
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma testosterone content of male patients with Parkinson's disease during L-dopa treatment with or without dopadecarboxylase inhibitor.
    Pekkarinen A; Rinne UK; Salokangas R; Siirtola T; Sonninen V
    Acta Neurol Scand Suppl; 1972; 51():129-30. PubMed ID: 4514339
    [No Abstract]   [Full Text] [Related]  

  • 20. Decrease of the 3,4-dihydroxyphenylalanine (DOPA) decarboxylase activities in human erythrocytes and mouse tissues after administration of DOPA.
    Tate SS; Sweet R; McDowell FH; Meister A
    Proc Natl Acad Sci U S A; 1971 Sep; 68(9):2121-3. PubMed ID: 5289372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.